The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA)-Reference-Cited by-同舟云学术

The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA)

Published:2017-12-15 Issue:4 Volume:36 Page:407-417
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Ghabri Salah,Autin Erwan,Poullié Anne-Isabelle,Josselin Jean Michel

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/article/10.1007/s40273-017-0602-5/fulltext.html

Reference54 articles.

1. Mauskopf J. Prevalence-based economic evaluation. Value Health. 1998;1(4):251–9.

2. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics. 2001;19(6):609–21.

3. Patented Medicine Prices Review Board (PMPRB). Budget impact analysis guidelines. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Ottawa. 2007. http://www.pmprb-cepmb.gc.ca/cmfiles/bia-may0738lvv-5282007-5906.pdf . Accessed 11 Dec 2017.

4. Conseil d’examen du prix des médicaments brevetés (CEPMB), Système national d’information sur l’utilisation des médicaments prescrits. Lignes directrices portant sur l’incidence du prix du médicament sur les budgets des régimes d’assurance-médicaments : évaluation des besoins. Ottawa. 2005. http://www.pmprb-cepmb.gc.ca/CMFiles/Publications/Analytical%20Studies/BIA-Final-F22NFG-10212005-8433.pdf . Accessed 11 Dec 2017.

5. Belgian Health Care Knowledge Centre (KCE). Belgium guidelines for economic evaluations and budget impact analyses: second edition. Brussels. 2012. https://kce.fgov.be/sites/default/files/page_documents/KCE_183_economic_evaluations_second_edition_Report.pdf . Accessed 11 Dec 2017.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A budget impact analysis of a digital monitoring solution in patients treated with oral anticancer agents: a medico-economic analysis of the randomized phase 3 CAPRI trial;The European Journal of Health Economics;2024-06-28

2. Budget impact analysis of breast cancer medications: a systematic review;Journal of Pharmaceutical Policy and Practice;2022-12-29

3. Budget impact analysis of a multifaceted nurse-led intervention to reduce indwelling urinary catheter use in New South Wales Hospitals;BMC Health Services Research;2022-08-05

4. Budget Impact Analysis of Impella CP® Utilization in the Management of Cardiogenic Shock in France: A Health Economic Analysis;Advances in Therapy;2022-01-23

5. Budget Impact Analysis of Diabetes Drugs: A Systematic Literature Review;Frontiers in Public Health;2021-11-19